Related Experiment Video
Updated: Jun 29, 2026

Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay
Published on: April 28, 2014
Increased burden of invasive group A streptococcal disease among Australian children, 2023-2024: a prospective cohort
Yara-Natalie Abo1,2,3,4, Jane Oliver1,5,6,7, Alissa McMinn1
1Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
Background:
Global rates of invasive Group A Streptococcus (iGAS) disease surged from September 2022, exceeding pre-COVID-19 pandemic levels, showing atypical seasonality and disproportionately affecting children. We previously described the epidemiology of iGAS among Australian children from mid-2018 to end 2022 using data from the Paediatric Active Enhanced Diseases network and here provide updated clinical epidemiology for 2023 and 2024 to help inform public health strategies.
Methods:
Prospective surveillance of 0-17-year-olds with iGAS admitted to six tertiary hospitals in five Australian states/territories in 2023 and 2024. Confirmed cases had GAS detected from ≥1 sterile site specimen; probable cases had detection of GAS in ≥1 non-sterile site specimen and diagnosis of septic shock, streptococcal toxic shock syndrome or necrotising fasciitis.
Findings:
In 2023, the annualised incidence was 5.10 per 100,000 (95% CI 4.50-5.75, n = 263 cases) and dropped significantly in 2024 (annualised incidence 2.13, 95% CI 1.75-2.57, n = 111 cases). Quarter three peaks were not as predominant across 2023 and 2024 compared to usual patterns. Intensive care unit admission occurred among 147/374 (39%) children with six deaths. At discharge, 137/374 (37%) had not returned to premorbid function. Respiratory virus co-infection was found among 133/267 (49.8%) patients tested and was associated with higher risk of severe disease, RR 1.6 (95% CI 1.26-2.07). Adjunctive clindamycin, linezolid or intravenous immunoglobulin was used in 201/374 (54%), including 126/147 (86%) of severe disease cases.
Interpretation:
We have captured the end of post-COVID-19 pandemic iGAS surge in sentinel Australian paediatric hospitals. High iGAS incidence peaked in 2023, before reducing to similar pre-pandemic incidence in 2024. The dynamic epidemiology and persistent burden of disease highlight the need for continued vigilant public health efforts, surveillance, and vaccine development.
Funding:
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Related Concept Videos
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin create...
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Prevalence and Incidence
Prevalence indicates the proportion of individuals in a population who have a specific disease or health condition at a...
Staphylococcal Skin Infections
Streptococcal Pharyngitis
Clinical Significance of Antibiotic Resistance

